title: [Clinico-morphological changes in ectropion after treatment with polydeoxyribonucleotide (PDRN)].
abstract: Thirty patients in fertile age affected by ectropion were treated with Polydeoxyribonucleotide (PDRN) (*) vaginal suppositories for 24 days. No other local or general therapy was allowed. The following parameters were evaluated: local symptomatology, tolerability and compliance, vaginal cytology, colposcopic examination, bioptic sampling of affected area prior to and after treatment, and local immune response. The results show the efficacy of PDRN. In fact, after the treatment: reduction of subjective symptomatology with decrease of average score for each symptom; excellent or good tolerability and acceptability; reduced inflammation; increased iodine-dark areas; reestablishment of normal balance in T- and B-lymphocytic populations have been found.
authors.affiliation: Istituto di Clinica Ostetrica e Ginecologia, Università di Pisa.
authors.forename: I
authors.initials: I
authors.lastname: De Luca Brunori
authors.forename: M
authors.initials: M
authors.lastname: Urbano
authors.forename: L
authors.initials: L
authors.lastname: Romani
authors.forename: A
authors.initials: A
authors.lastname: Tarani
authors.forename: R
authors.initials: R
authors.lastname: Felipetto
authors.forename: L
authors.initials: L
authors.lastname: Battini
authors.forename: A
authors.initials: A
authors.lastname: Amato
authors.forename: P
authors.initials: P
authors.lastname: Andreoni
mesh_terms: D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000166:cytology / Q000473:pathology; D003127:Colposcopy; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D013488:Suppositories; D002577:Uterine Cervical Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D014626:Vaginal Smears
chemical_list: D011089:Polydeoxyribonucleotides; D013488:Suppositories
vernacular_title: Modificazioni clinico-morfologiche dell'ectropion dopo trattamento con polidesossiribonucleotide (PDRN).